[1]
|
Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C., Ferrario, F., Flores-Suarez, L.F., Gross, W.L., Guillevin, L., Hagen, E.C., Hoffman, G.S., Jayne, D.R., Kallenberg, C.G., Lamprecht, P., Langford, C.A., Luqmani, R.A., Mahr, A.D., Matteson, E.L., Merkel, P.A., Ozen, S., Pusey, C.D., Rasmussen, N., Rees, A.J., Scott, D.G., Specks, U., Stone, J.H., Takahashi, K. and Watts, R.A. (2013) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatology, 65, 1-11. https://doi.org/10.1002/art.37715
|
[2]
|
Mahr, A., Guillevin, L., Poissonnet, M. and Ayme, S. (2004) Prevalences of Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener’s Granulomatosis, and Churg-Strauss Syndrome in a French Urban Multiethnic Population in 2000: A Capture-Recapture Estimate. Arthritis & Rheumatology, 51, 92-99. https://doi.org/10.1002/art.20077
|
[3]
|
Watts, R.A., Gonzalez-Gay, M.A., Lane, S.E., Garcia-Porrua, C., Bentham, G. and Scott, D.G. (2001) Geoepidemiology of Systemic vasculitis: Comparison of the Incidence in Two Regions of Europe. Annals of the Rheumatic Diseases, 60, 170-172. https://doi.org/10.1136/ard.60.2.170
|
[4]
|
Karras, A. (2019) Renal Involvement of Anti-Neutrophil Cytoplasm Antibody Vasculitis. EMC-Nephrologie, 16, 1-10.
|
[5]
|
Terrier, B. (2019) Treatment of Vasculitis at ANCA: Certainties and Controversies. Néphrologie & Thérapeutique, 15, S7-S12. https://doi.org/10.1016/j.nephro.2019.02.008
|
[6]
|
Mukhtyar, C., Guillevin, L., Cid, M.C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C.G., Merkel, P.A., Raspe, H., Salvarani, C., Scott, D.G., Stegeman, C., Watts, R., Westman, K., Witter, J., Yazici, H. and Luqmani, R., for the European Vasculitis Study Group (2009) EULAR Recommendations for the Management of Primary Small and Medium Vessel Vasculitis. Annals of the Rheumatic Diseases, 68, 310-317. https://doi.org/10.1136/ard.2008.088096
|
[7]
|
Berti, A., Cornec, D., Crowson, C.S., Specks, U. and Matteson, E.L. (2017) The Epidemiology of Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota. Arthritis & Rheumatology, 69, 2338-2350. https://doi.org/10.1002/art.40313
|
[8]
|
Puecha, X. (2007) Vasculitis Associated with Polymorphonuclear Anticytoplasm Antibodies.
|
[9]
|
Yamada, Y., Harada, M., Hara, Y., Iwabuchi, R., Hashimoto, K., Yamamoto, S. and Kamijo, Y. (2021) Efficacy of Plasma Exchange for Antineutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis: A Systematic Review and Meta-Analysis. Arthritis Research & Therapy, 23, Article No. 28. https://doi.org/10.1186/s13075-021-02415-z
|
[10]
|
Walsh, M., Merkel, P.A., Peh, C.A., Szpirt, W.M., Puéchal, X., Fujimoto, S., Hawley, C.M., Khalidi, N., Floßmann, O., Wald, R., Girard, L.P., Levin, A., Gregorini, G., Harper, L., Clark, W.F., Pagnoux, C., Specks, U., Smyth, L., Tesar, V., Ito-Ihara, T., de Zoysa, J.R., Szczeklik, W., Flores-Suárez, L.F., Carette, S., Guillevin, L., Pusey, C.D., Casian, A.L., Brezina, B., Mazzetti, A., McAlear, C.A., Broadhurst, E., Reidlinger, D., Mehta, S., Ives, N., Jayne, D.R.W., for the PEXIVAS Investigators (2020) Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. The New England Journal of Medicine, 382, 622-631. https://doi.org/10.1056/NEJMoa1803537
|
[11]
|
Kronbichler, A., Shin, J.I., Wang, C.S., Szpirt, W.M., Segelmark, M., Tesar, V. (2021) Plasma Exchange in ANCA-Associated Vasculitis: The Pro Position. Nephrology Dialysis Transplantation, 36, 227-231. https://doi.org/10.1093/ndt/gfaa311
|
[12]
|
Specks, U., Fussner, L.A., Cartin-Ceba, R., Casal Moura, M., Zand, L., Fervenza, F.C. (2021) Plasma Exchange for the Management of ANCA-Associated Vasculitis: The Con Position. Nephrology Dialysis Transplantation, 36, 231-236. https://doi.org/10.1093/ndt/gfaa312
|
[13]
|
Chung, S.A., Langford, C.A., Maz, M., Abril, A., Gorelik, M., Guyatt, G., et al. (2021) 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care & Research, 73, 1088-1105. https://doi.org/10.1002/acr.24634
|
[14]
|
Furuta, S., Nakagomi, D., Kobayashi, Y., Abril, A., Gorelik, M., Guyatt, G., Archer, A.M., Conn, D.L., Full, K.A., Grayson, P.C., Ibarra, M.F., Imundo, L.F., Kim, S., Merkel, P.A., Rhee, R.L., Seo, P., Stone, J.H, Sule, S., Sundel, R.P., Vitobaldi, O.I., Warner, A., Byram, K., Dua, A.B., Husainat, N., James, K.E., Kalot, M.A., Lin, Y.C., Springer, J.M., Turgunbaev, M., Villa-Forte, A., Turner, A.S., Mustafa, R.A., for the LoVAS Collaborators (2021) Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA, 325, 2178-2187. https://doi.org/10.1001/jama.2021.6615
|
[15]
|
French Group for the Study of Vasculitis GFEV (2019) Update of the PNDS Systemic Necrotizing Vasculitis. https://www.vascularites.org
|
[16]
|
Jones, R.B., Tervaert, J.W., Hauser, T. Luqmani, R., Morgan, M.D., Peh, C.A., Savage, C.O., Segelmark, M., Tesar, V., van Paassen, P., Walsh, D., Walsh, M., Westman, K. and Jayne, D.R., for the European Vasculitis Study Group (2010) Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. The New England Journal of Medicine, 363, 211-220. https://doi.org/10.1056/NEJMoa0909169
|
[17]
|
Stone, J.H., Merkel, P.A., Seo, P. Langford, C.A., Hoffman, G.S., Kallenberg, C.G., St Clair, E.W., Turkiewicz, A., Tchao, N.K., Webber, L., Ding, L., Sejismundo, L.P., Mieras, K., Weitzenkamp, D., Ikle, D., Seyfert-Margolis, V., Mueller, M., Brunetta, P., Allen, N.B., Fervenza, F.C., Geetha, D., Keogh, K.A., Kissin, E.Y., Monach, P.A., Peikert, T., Stegeman, C., Ytterberg, S.R. and Specks, U. (2010) Rituximab versus Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Trial (RAVE). The New England Journal of Medicine, 363, 221-232. https://doi.org/10.1056/NEJMoa0909905
|
[18]
|
Jayne, D.R.W., Gaskin G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C.O., Sinico, R.A., et al., for the European Vasculitis Study Group (2007) Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis. Journal of the American Society of Nephrology, 18, 2180-2188. https://doi.org/10.1681/ASN.2007010090
|
[19]
|
Guillevin, L., Charles, P., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., et al., for the French Vasculitis Study Group (2014) Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. The New England Journal of Medicine, 371, 1771-1780. https://doi.org/10.1056/NEJMoa1404231
|
[20]
|
Specks, U., Merkel, P.A., Seo, P., Spiera, R., Langford, C.A., Hoffman, G.S., et al., for the RAVE-ITN Research Group (2013) Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. The New England Journal of Medicine, 369, 417-427. https://doi.org/10.1056/NEJMoa1213277
|